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ABSTRACT 
Objective: This study aimed to evaluate the effectivity of resveratrol-gold-PEG-folate (RSV-Au-PEG-FA) nanoparticles formulation in resveratrol 
(RSV) targeted delivery and cytotoxicity effect on HeLa human cervical cancer cell line. 
Methods: Gold nanoparticles (AuNP) were used as carriers and folic acid (FA) was used as active targeting moiety, using polyethylene glycol-bis-
amine (PEG-bis-amine) as linker. RSV-Au-PEG-FA nanoparticles were characterized by UV-Vis spectrophotometry, infrared spectroscopy, particle 
size analyzer (PSA), and transmission electron microscopy (TEM). Cellular uptake study was conducted by using fluorescence microscope. 
Cytotoxicity study was conducted by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
Results: Cellular uptake study has shown that RSV-Au-PEG-FA nanoparticles are potential to be accumulated intracellularly in HeLa cells more than 
in Vero cells. Cytotoxicity study has shown RSV-Au-PEG-FA nanoparticles IC50 67.06±2.14 µM and RSV IC50
Conclusion: RSV-Au-PEG-FA nanoparticles are potential to enhance RSV uptake by HeLa cells selectively.  
 9.66±1.44 µM on HeLa cells 
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INTRODUCTION 
Resveratrol (trans-3,5,4’-trihydoxystilbene) is lipophilic polyphenol 
obtained from grape plant (Vitis vinifera) and melinjo seeds (Gnetum 
gnemon L.) [1-3]. The activities of resveratrol (RSV) as anticancer 
have been reported. RSV has the ability to inhibit the expression of 
anti-apoptotic proteins and increase the expression of pro-apoptotic 
proteins [4, 5]. RSV is able to increase p53 protein level and inhibit 
the proliferation of cancer cells by increasing cells accumulation at 
G1/S phase via aryl hydrocarbon receptor (AHR) [6]. RSV is also able 
to inhibit the transcription of enzyme which contributes in 
metastasis process from tumor [7].  
However, RSV lacks the ability to target cancer cells selectively, 
which limits its usage as anticancer. RSV induces apoptosis when 
used at high dose (10-100 µM) on cancer cells and normal cells [8, 
9]. RSV usage at ≥ 10 µM induces apoptosis of normal rat thymocytes 
[9]. RSV usage in great concentration (60 µM) inhibits the growth 
and induces apoptotic effect on CD34+precursor cells [10]. RSV 
inhibits proliferation and causes toxic effect on 10ScNCr/23 mouse 
macrophages (IC50
Gold nanoparticle (AuNP) is metal nanoparticle which is well-known 
for its biocompatible, easy to prepare, and ready to modify with 
active ligand. AuNP has intense and specific surface plasmon 
resonance absorption, hence, easy to characterize [12-15]. Folic acid 
(FA) usage as active targeting moiety is based on specific 
overexpression of folate-binding protein found in epithelial cancer 
cells (MDA-MB-231, KB 3-1, and HeLa cells) [16-19]. The study of 
combination usage of AuNP as RSV nanocarriers and FA as targeting 
moiety have been done previously where resveratrol-gold-PEG-
folate (RSV-Au-PEG-FA) nanoparticles were successfully prepared. 
However, the effectivity of RSV-Au-PEG-FA nanoparticles in 
improving selectivity of RSV on cancer cells haven’t been studied yet 
[20].  
 29.0 µM) [11]. Active targeting system might be 
an alternative effort to overcome this limitation. 
In this study, RSV was formulated by using AuNP as carriers, FA as 
targeting moiety, and PEG-bis-amine as linker. The RSV-Au-PEG-FA 
nanoparticles were characterized by UV-Vis spectrophotometry, 
infrared spectroscopy, particle size analyzer (PSA), and transmission 
electron microscopy (TEM). In order to see the effectivity of RSV-Au-
PEG-FA nanoparticles, cellular uptake study and cytotoxicity study 
was conducted on HeLa human cervical cancer cell line. 
MATERIALS AND METHODS 
Materials 
Resveratrol (RSV) ≥ 99%, HAuCl4 30%, PEG-bis-amine (MW 3400 
g/mol), folic acid (FA) ≥ 97% (MW 441.40 g/mol), N-(-3-
Dimethylaminopropyl)-N’-ethylcarbodiimide (EDC), N-
hydroxysuccinimide (NHS) 98%, trisodium citrate (Sigma Aldrich, 
Singapore), cisplatin (Dankos, Indonesia), HeLa (ATCC CCL-2) 
human cervical cancer cell line, Vero (ATCC
Preparation of PEG-FA conjugate 
 CCL-81) normal kidney 
epithelial cell line from African green monkey (American Type Culture 
Collection, USA), dulbecco’s modified eagle medium (DMEM), fetal 
bovine serum (FBS) 10%, penicillin-streptomycin 1%, phosphate 
buffered saline (PBS), trypsin 0.125%, typan blue 0.1%, 
paraformaldehyde 4%, fluorescein isothiocyanate (FITC), and [3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) 0.5%. 
Twenty-five milligrams of FA were conjugated to 250 mg PEG-bis-
amine (1.5:1.0 in molar ratio) with 300 mg EDC and 100 mg NHS in 
0.5 ml dimethyl sulfoxide (DMSO). The reaction was accelerated 
with 0.5 ml HCl 2% and stirred for 5 h at room temperature. PEG-FA 
conjugates were kept in 15 °C until further usage [21]. 
Preparation of AuNP 
Ten milliliters of HAuCl4
Preparation of RSV-Au-PEG-FA nanoparticles 
 1 mmol was heated until it began to boil 
and 0.282 ml trisodium citrate 130 mmol was quickly added while 
the heating and stirring were proceeded for 15 min until the red-
burgundy AuNP was formed. The heating was stopped and the 
stirring continued until the temperature of mixture decreased to 
room temperature [22]. 
One hundred milligrams of PEG-FA conjugate were added to 10 ml 
AuNP and stirred for 4 h at room temperature. The mixture was 
added with 2.28 ml RSV 600 µg/ml and stirred for 2 h at room 
temperature. The RSV-Au-PEG-FA nanoparticles were purified by 
centrifugal-ultrafiltration using Vivaspin 2 (MW 2000 Da) (2000 
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rpm; 30 min) to remove unreacted molecules (MW<2000 Da) such 
as NHS, EDC, and unreacted FA. The residue and filtrate layers were 
collected respectively and kept in 15°C until further studies [14]. 
RSV-Au-PEG-FA nanoparticles characterization 
RSV-Au-PEG-FA nanoparticles were detected using UV-Vis Jasco V-530 
spectrophotometer and FTIR 8400S/IRPrestrige with DRS 8000. The 
particle size, polydispersity index (PDI), and zeta potential of RSV-Au-
PEG-FA nanoparticles were measured with Horiba SZ-100 particle size 
analyzer. The morphology of RSV-Au-PEG-FA nanoparticles were 
observed by Tecnai G2 20 S-Twin transmission electron microscope. 
% Drug loading (%DL) 
To determine %DL of loaded RSV in RSV-Au-PEG-FA nanoparticles, 
indirect method was used. The amount of free RSV in filtrate was 
determined by HPLC system. HPLC system consisted of HPLC 
Shimadzu LC-20AT pump, UV-Vis SPD-10A detector, and Inertsil 
ODS-3 column with 250 mm in length, 5 µm particle diameter, 4.6 
mm i.d. Reversed phase HPLC was performed using isocratic eluent 
water: acetonitrile (3:1) pH 3 adjusted by glacial acetate acid with 
flow rate 1.5 ml/min. The analysis was performed at 25°C and 
detected at 306 nm. Standards and samples were filtered with 0.45 
µm filter membrane and 20 µl of each was injected to system [23]. 
For quantification, a standard calibration curve was done ranging 1 
to 25 µg/ml. The square regression coefficient of analytical curve 
was r2
%DL = (W
= 0.9986 (r=0.9992). Data were processed by LC-Solution 
software. %DL is determined using:  
t-Wf)/Wt
Where W
 x 100% 
t is the total amount of RSV added in the formulation and 
Wf
Cell culture 
 is the amount of free RSV in filtrate. 
Cellular uptake study of RSV-Au-PEG-FA nanoparticles was 
evaluated on HeLa cells and Vero cells. Cytotoxicity study was 
evaluated on HeLa cells. HeLa and Vero cell lines were cultured in 
DMEM supplemented with FBS 10% and penicillin-streptomycin 1% 
in cell culture flask. Cells were routinely propagated and kept in 
incubator (37 °C; 5% CO2
Cellular uptake study 
) [4, 24, 25]. 
One milliliter of FITC 10 µg/ml were added to 1 ml of RSV-Au-PEG-
FA nanoparticles and kept at 15 °C overnight [26]. Each 500 µl of cell 
culture containing 104 of HeLa and Vero cells, respectively, were 
seeded into 8-slide chambers and incubated at 37°C and 5% CO2 for 
24 h. Culture medium were removed and wells were washed 3 times 
by PBS. Cells were fixed by 200 µl paraformaldehyde 4% and 
incubated for 1 h. Culture mediums were removed and wells were 
washed 3 times by PBS. The HeLa and Vero cells were added with 
200 µl of FITC-RSV-Au-PEG-FA and incubated 
Cytotoxicity study 
for 30 min. The 
samples were removed and the chambers were peeled. The 
coverslip was placed onto fluorescence microscope slide. The light 
filter was set into B-2A filter to observe cellular uptake of FITC-RSV-
Au-PEG-FA in HeLa and Vero cells. 
The cytotoxicity of RSV-Au-PEG-FA nanoparticles against HeLa cells 
was assessed by MTT assay. One hundred microliters of cell culture 
containing 104 of HeLa cells were seeded into 96-well plate and 
incubated at 37 °C and 5% CO2 
RESULTS AND DISCUSSION 
for 24 h. Culture mediums were 
removed and wells were washed 3 times with PBS [27]. The cells 
then incubated with mediums containing series of concentration (3 
to 120 µM) of RSV-Au-PEG-FA nanoparticles, RSV, and cisplatin for 
24 h [28]. Controls were performed by adding DMSO 0.28% to plate. 
The samples were removed and washed 3 times with mediums. Ten 
microliters of MTT 0.5 mg/ml in medium were added into each well 
and incubated for 4 h. The MTT were removed and 100 µl of 
absolute ethanol was added to each well to solute formazan crystals. 
The absorbances were measured with a Bio-Rad microplate reader 
at 595 nm. The relative cell viability was expressed as the 
percentage of negative control. 
Preparation of RSV-Au-PEG-FA nanoparticles 
In preparation of AuNP, the yellow HAuCl4was reduced into red-
burgundy AuNP, indicating AuNP was successfully formed. The 
preparation of AuNP followed Turkevich method where trisodium 
citrate as weak reducing agent using heat as energy source to reduce 
Au3+in HAuCl4
 
 into Au ° in AuNP [29]. The PEG-FA conjugation 
process involving the activation of carboxyl group of FA by EDC and 
NHS where the carboxyl group was substituted into NHS group 
forming intermediate folate-NHS. The NHS group further substituted 
with amine group from PEG-bis-amine where new covalent amide 
bond was formed resulting PEG-FA conjugate [30, 31]. The red-
burgundy of AuNP turned into darker after added with PEG-FA 
conjugate and RSV, indicating the particle size was increasing and 
interactions among AuNP, PEG-FA conjugate, and RSV forming into 
RSV-Au-PEG-FA nanoparticles (fig. 1). 
 
Fig. 1: Effect of tablet geometry on drug release 
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Fig. 2: UV-Vis spectrums of resveratrol, gold nanoparticles, PEG-bis-amine, folic acid, RSV-Au-PEG-FA nanoparticles residue, and RSV-Au-
PEG-FA nanoparticles filtrate 
 
 
Fig. 3: Infrared spectrums of resveratrol, PEG-bis-amine, folic acid, and RSV-Au-PEG-FA nanoparticles 
 
Characterization of RSV-Au-PEG-FA nanoparticles 
The comparative UV-Vis spectrums of RSV, AuNP, PEG-bis-amine, 
FA, RSV-Au-PEG-FA nanoparticles residue, and RSV-Au-PEG-FA 
nanoparticles filtrate were presented in fig. 2. RSV and AuNP 
respectively showed maximum absorption at λmax
The comparative FTIR spectrums of RSV-Au-PEG-FA nanoparticles, 
RSV, PEG-bis-amine, and FA were shown in fig. 3. There was similar 
peak of RSV-Au-PEG-FA nanoparticles with PEG-bis-amine and FA. 
The peak at 1611 cm
 298.5 and 532 
nm. RSV-Au-PEG-FA nanoparticles in residue layer showed 
characteristics peak at 296.5 nm and 534 nm, which was similar to 
peak of RSV and AuNP, indicating RSV was successfully loaded into 
nanoparticles. RSV-Au-PEG-FA nanoparticles filtrate showed one 
peak at 300 nm with similar characteristic with RSV, indicating 
centrifugal ultrafiltration method was effective to purify RSV-Au-
PEG-FA nanoparticles from unreacted RSV. 
-1 and 1699 cm-1 in FA were referred to amide I 
and II bands, which was also found in RSV-Au-PEG-FA nanoparticles 
(1544 cm-1 and 1722 cm-1). The peak at 1107 cm-1 in PEG-bis-amine 
referred to C-N stretch also found in RSV-Au-PEG-FA nanoparticles 
(1115 cm-1). Meanwhile, the peak C=C aromatic of RSV (836 cm-1
The particle size, polydispersity index (PDI), zeta potential, and 
drug loading of RSV-Au-PEG-FA nanoparticles were presented in 
table 1 and fig. 4. The particle size and PDI are important 
parameters to predict stability of nanoparticles and its clinical 
utilization. As seen in table 1, the z-average of RSV-Au-PEG-FA 
nanoparticles was<100 nm, indicating that based on particle size 
alone, RSV-Au-PEG-FA nanoparticles were potentially prevented 
from cellular internalization by phagocytic cells such as 
macrophages, neutrophils, and dendritic cells in blood vessels, 
which mainly happened to nanoparticles with 100-150 nm in size. 
At the same time, the particle size of RSV-Au-PEG-FA nanoparticles 
was not less than 10 nm, indicating that RSV-Au-PEG-FA 
nanoparticles was potentially large enough not to distribute to 
normal tissues through small pores such as glomerulus in kidney 
(10-15 nm) [34]. The PDI is a parameter used to define the degree 
of uniformity of particle size distribution. Large PDI value (>0.7) 
indicates the sample has broad size range in particle size 
distribution, related to instability of particles in colloid system. 
The PDI value of RSV-Au-PEG-FA nanoparticles was<0.7 indicating 
that RSV-Au-PEG-FA nanoparticles had homogenously 
monodisperse system. Zeta potential is a parameter which reflect 
on stability of nanoparticles in colloid system and also can be used 
to define surface property of nanoparticles. Zeta potential values 
greater than ±30 mV permits stable colloid system. The zeta 
potential of RSV-Au-PEG-FA nanoparticles was greater than-30 
mV. This indicated that there’s great repulsive forces among the 
particles, preventing aggregation of particles and resulting 
relatively stable colloid system [35]. However, the negative charge 
particles are prone to interact with phagocytic cells compared to 
) 
was not visible in RSV-Au-PEG-FA nanoparticles, which was contrary 
to UV-Vis spectrophotometry result. This indicated RSV was 
potentially loaded in RSV-Au-PEG-FA nanoparticles [32, 33]. 
Sutriyo et al. 
Int J App Pharm, Vol 12, Issue 4, 2020, 113-118 
116 
positive charge particles in similar size, presumably because of 
similarity with negative charge of bacteria [36]. 
Based on morphology analysis using TEM, RSV-Au-PEG FA 
nanoparticles have spherical shape, as seen in fig. 5. Based on 
previous studies, particle shape may influence the movement of 
nanoparticles in circulation system and cellular uptake process. Rod-
shaped nanoparticles are more likely to marginate towards vessel 
wall compared to spherical nanoparticles, which may interrupt 
delivery and targeting process [37]. The cellular uptake of spherical 
gold nanoparticles is higher than rod-shaped gold nanoparticles 
[38]. The % DL of RSV-Au-PEG-FA nanoparticles was 88.87±0.25%. 
 
Table 1: Particle size distribution, polydispersity index, and zeta potential of RSV-Au-PEG-FA nanoparticles 
RSV-Au-PEG-FA 
Z-average (nm) 31.57±1.80 
Dv10 11.97±1.75 (nm) 
Dv50 16.37±1.89 (nm) 
Dv90 27.10±1.80 (nm) 
Polydispersity Index (PDI) 0.321±2.21 
Zeta Potential (mV) -53.63±0.40 
Data represented mean±SD (n=3) 
 
 
Fig. 4: Particle size distribution of RSV-Au-PEG-FA nanoparticles by volume 
 
 
Fig. 5: TEM image of RSV-Au-PEG-FA nanoparticles 
 
 
Fig. 6: Fluorescence microscopy images of (A) HeLa cells, (B) HeLa cells in FITC-RSV-Au-PEG-FA, (C) Vero cells, (D) Vero cells in FITC-RSV-
Au-PEG-FA 
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Fig. 7: Graphics of HeLa cells viability in (A) RSV-Au-PEG-FA nanoparticles and (B) free RSV, data represented mean±SD (n=3) 
 
Cellular uptake study 
After HeLa and Vero cells were incubated with FITC-RSV-Au-PEG-FA 
nanoparticles for 30 min, FITC-RSV-Au-PEG-FA nanoparticles were 
both accumulated in both cells, which is shown in fig. 6. The 
fluorescence of FITC-RSV-Au-PEG-FA nanoparticles were more 
intense in HeLa cells compared to Vero cells, indicating the cellular 
uptake of RSV-Au-PEG-FA nanoparticles in HeLa cells was 
potentially greater than in Vero cells. 
As reported before, high affinity folate receptor (FR) is highly expressed 
on numerous malignant cells, including HeLa cervical cancer cells. 
Meanwhile, FR receptor has been found at low levels in normal kidney, 
lung, and thyroid. FR located on the surface of cancer cell mediates the 
drug-folate conjugate in similar manner to free folic acid into the cancer 
cell by endocytosis. The acidic environment of endosome disassociates 
folate from receptor and drug is released [16, 18, 39]. 
In this study, RSV-Au-PEG-FA nanoparticles potentially interacted 
with overexpressed FRs on surface of HeLa cells which lead to 
endocytosis of RSV-Au-PEG-FA nanoparticles. Meanwhile, Vero cells 
has low levels of FRs, which subsequently caused to less interaction 
between RSV-Au-PEG-FA nanoparticles with FR and less endocytosis 
of RSV-Au-PEG-FA nanoparticles into Vero cells. This indicated that 
FA usage as targeting moiety was potentially suitable in RSV 
formulation to treat cancer selectively. 
Cytotoxicity study 
The cytotoxicity effect of RSV-Au-PEG-FA nanoparticles and free RSV 
on HeLa cells over range of concentrations were represented in fig. 
7. After 24 h of incubation with RSV-Au-PEG-FA nanoparticles, doses 
up from 3.09 to 24.73 µM were ineffective and toxicity appeared to 
start at 49.45 µM with cell viability 61.17±1.18%. Meanwhile with 
RSV, the cell viability at concentration 60 µM was already 
19.64±0.29%. After data plot, IC 50 RSV-Au-PEG-FA nanoparticles 
(67.06±2.14 µM) was higher than IC50
With result of cellular uptake study, enhancement of RSV-Au-PEG-FA 
nanoparticles uptake into cancer cells doesn’t guarantee RSV-Au-
PEG-FA nanoparticles are more potent than free RSV, because toxic 
effect still depends on nanocarrier’s ability to release RSV into 
cancer cells and RSV endurance in cellular environment (lysosome 
and exocytosis) to be functional as anticancer [41-43]. 
 RSV (9.66±1.44 µM). The 
DMSO (0.28%) didn’t affect the viability of control cells. This 
indicated that RSV-Au-PEG-FA nanoparticles needs higher 
concentration than free RSV to cause toxic effect on HeLa cells. This 
is contrary to previous studies in which RSV in nanoparticles form 
were generally more toxic than free RSV [31, 40]. 
Based on cellular uptake study and cytotoxicity study, it’s predicted 
that RSV-Au-PEG-FA nanoparticles haven’t fully released yet in 
endosomal environment of HeLa cells. This might be caused by 
linker type used was forming strong and stable bond even in cellular 
environment which inhibited the release of RSV from RSV-Au-PEG-
FA nanoparticles. In previous study, polyvinyl alcohol was used as 
linker and nanoparticles formed needed lower concentration than 
free RSV to cause toxic effect on cancer cells [40]. 
CONCLUSION 
Cellular uptake study showed that the fluorescence of RSV-Au-PEG-
FA nanoparticles were more intense in HeLa cells compared to Vero 
cells. Cytotoxicity study has shown that IC50 RSV-Au-PEG-FA 
nanoparticles (67.06±2.14 µM) was higher than IC50
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